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Summary
Acute and recurrent urinary tract infections (UTIs) are
common auto-infectious diseases transmitted from the in-
testinal tract. They affect the urinary tract either through
recurrence or through persistence. The incidence of UTIs
increases with age and comorbidities. In this guideline
from the Swiss Society of Gynaecology and Obstetrics
(SSGO), diagnosis and treatment of UTIs are grouped
into uncomplicated and complicated cases. This is to our
knowledge the first guideline that specifically considers
UTIs in pregnancy and breastfeeding, and the prevention
of UTIs in the context of urogynaecological diagnosis and
surgery. Recommendations are based on observational,
retrospective or randomised controlled studies. The level
of evidence was rated according to recommendations
made by the Oxford Centre of Evidence-based Medicine.
In non-pregnant women and women <65 years with dy-
suria, pollakiuria and suprapubic pain, no urine diagnostic
testing is needed. If the clinical presentation is unclear, uri-
nary tests such as midstream urine stix or urine analysis
should be used, and in cases of unclear or recurrent infec-
tions, a urine culture.
Routine screening for asymptomatic bacteriuria (ASB)
should not be carried out, and antibiotic treatment should
be avoided in cases of incidentally detected ASB. As an
exception, screening for bacteriuria should be carried out
in patients prior to urogynaecological surgery where uri-
nary drainage by catheter is necessary or probable. In
pregnancy, systematic screening for ASB is not recom-
mended, because most women with ASB do not develop
complications during follow-up, and contamination of urine
samples collected in pregnancy is common.
Patients should be advised that most UTIs are self-limit-
ing, that the symptoms can be relieved with non-steroidal
anti-inflammatory drugs (NSAIDs) and that the same time
is required to eradicate the bacteria using antibiotics or
NSAIDs. For non-pregnant women with uncomplicated
UTIs, a 48-hour-delayed antibiotic prescription is recom-
mended, supplemented by NSAIDs for pain relief. If an-
tibiotics are needed after 48 hours, or in case of direct
antibiotic administration in pregnant women, the shortest
possible course of treatment should be carried out.
There is increasing interest in alternatives or complemen-
tary treatments to antibiotic therapy, especially for recur-
rent UTIs. Different recommendations and alternative
medications are summarised.
This short and comprehensive guideline provides quick
answers for every day clinical questions concerning UTIs,
especially for obstetricians and gynaecologists.
Keywords: urinary tract infection, pyelonephritis, recur-
rent urinary tract infection, urinalysis, antibiotic therapy,
Escherichia coli
Background
The Quality Assurance Committee of the SSGO (Swiss
Society of Gynaecology and Obstetrics) releases guide-
lines on current topics to ensure quality and the timely im-
plementation of medical innovations. In human medicine,
the number of infections caused by antibiotic-resistant bac-
teria has increased. The urinary tract pathogen Escherichia
coli, which is often encountered in general and gynaeco-
logical practices, accounts for almost one third of resistant
bacteria. Further, new Swiss data confirm that the resis-
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As most guidelines on urinary tract infections (UTIs) (table
1) do not specifically consider the treatment of women and
do not include the treatment of pregnant women, the Qual-
ity Assurance Committee of the SSGO declared an expert
recommendation focusing on female UTIs in both pregnant
and non-pregnant women to be an urgent need. A guideline
was also required in the light of the strategy of the Federal
Office of Public Health to reduce antibiotic resistance.
UTIs in men are less frequent, but can be more serious than
in women owing to functional and anatomical differences
in the urogenital tract. Thus, diagnosis and treatment differ
between men and women. UTIs in men are not a topic of
this guideline.
Scope and aims
In this guideline on the management of UTIs, we report on
the diagnosis and treatment of UTIs and recurrent UTIs in
women and during pregnancy, with antibiotic and non-an-
tibiotic options. The guideline also covers antibiotic thera-
py prior to interventions and operations in gynaecology.
Guideline assembly and conflicts of interest
The expert panel comprises members of the SSGO, in-
cluding gynaecologists, obstetricians and urogynaecolo-
gists, and an infectiologist. This guideline meets the fol-
lowing requirements: it addresses UTIs and recurrent UTIs
in pregnant and non-pregnant women, it is presented in
a compressed, easy-to-understand text form, with practice
recommendations for in- and outpatients including evi-
dence-based recommendations (the search strategy is de-
scribed below), and is regularly updated every 3 to 4 years.
The members of the Quality Assurance Committee of the
SSGO are gynaecologists working in private practices, in
academia, and in regional and teaching hospitals. They
have various specialisations and sub-specialisations in ob-
stetrics and gynaecology. In addition, a representative of
the Swiss Patient Organisation (SPO) is also a permanent
committee member. The expert panel addresses UTIs, a
day-to-day problem of Ob/Gyn practitioners nation- and
worldwide, in the form of a consensus document and not as
a systematic review. The committee discussed the manage-
ment of UTIs during a series of meetings. A manual litera-
ture search was performed to reference statements on diag-
nostics and treatments where appropriate. A review of the
literature, including the Pubmed, Embase and Cochrane
Library databases, as well as conference proceedings of the
relevant professional societies, was carried out to rate the
level of evidence (LoE) and to search existing guidelines.
The search for evidence used keywords (MeSH terms)
grouped into the following syntax: (urinary tract infection)
OR (recurrent urinary tract infection) AND (controlled)
AND (randomised controlled trial [Publication Type] OR
(randomised AND controlled AND trial [Title / Abstract]).
Keywords used alone and/or in combination included the
following: women, pregnancy, national, international
guidelines, urodynamics, gynecologic surgery, pelvic floor
surgery, antibiotics, phytotherapy, D-mannose, E. coli. The
search was restricted to articles in English, German,
French, Italian and Spanish that were published up to the
end of December 2019. We assessed the LoE according to
the recommendations from the Oxford Centre of Evidence-
based Medicine (OCEBM, Levels of Evidence working
Group. 2011, https://www.cebm.net/2016/05/ocebm-lev-
els-of-evidence/).
The discussions about the recommendations took place in
parallel in the Quality Assurance Committee and in the
Swiss Working Group of Urogynaecology. The first and
the last author of this publication were responsible for fi-
nalising the decisions, which were taken by consensus.
All authors declared no conflict of interests; no companies
were involved; regular meetings of the members of the SS-
GO were financed according to the regulations of the soci-
ety with no extra compensation.
Table 1: National and international guidelines on urinary tract infections addressing UTIs in adults. Guidelines for children, immunocompromised patients or patients with urinary
catheters are not listed.
Guideline Country, region Year of re-
lease
Gender
American Urological Association (AUA)/Canadian Urological Association (CUA)/Society of Urodynamics, Female
Pelvic Medicine and Urogenital Reconstruction (SUFU): Guideline on recurrent uncomplicated urinary tract infections
in women (2019) [2]
USA, Can 2019 Women, not preg-
nant
Guideline Harnwegsinfekt (HWI) – Society of Infectious disease [3]
Available in German and French
CH 2020 Women
Deutsche Gesellschaft für Allgemeinmedizin und Familienmedizin (DEGAM):




Urinary tract infection (2): antimicrobial prescribing. NICE guideline (NG109) [5] UK 2018 Women, men
Executive summary of the diagnosis and treatment of urinary tract infection: guidelines of the Spanish Society of Clini-
cal Microbiology and Infectious Diseases (SEIMC) [6]
E 2018 Women, men





Interdisziplinäre S3 Leitlinie. Epidemiologie, Diagnostik, Therapie, Prävention und Management unkomplizierter, bak-
terieller, ambulant erworbener Harnwegsinfektionen bei erwachsenen Patienten [8]
Available in German




Recurrent urinary tract infection. Urogynaecology Committee; Family Physicians advisory Committee [9] Can 2010 Women, men
International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women:
A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infec-
tious Diseases [10]
EU, USA 2011 Women
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Epidemiology and definitions
Female acute UTIs are amongst the most common bacte-
rial infections seen by gynaecologists. Half of all women
experience UTIs, and at least a quarter of these experience
a recurrence. UTIs heal spontaneously at a high rate of
50−70%, and only 0.4−2.6% of uncomplicated UTIs de-
velop into pyelonephritis if left untreated [12, 13].
Urinary tract infections can be categorised in uncompli-
cated or complicated UTIs or asymptomatic bacteriuria
(ASB) (table 2). Recurrent UTIs, at least two infections
within 6 months or three infections within a year, can be
uncomplicated or complicated. Urine itself is not sterile.
Between 1% and 3% of young women and 14−22% of
postmenopausal, community-dwelling women have ASB
[14].
Diagnostics
Uncomplicated urinary tract infections do not require diag-
nostic tests. The following tests are available for cases with
an unclear clinical presentation:
Midstream urine stix: sensitivity 75%, specificity 82% for
leucocyte esterase (proof of leucocytes in urine) [15].
Urine analysis is reliable only if the sample is not conta-
minated, i.e., <10 squamous cells/high power field. Mid-
stream urine samples, if collected correctly, have a sensi-
tivity of 95% and a specificity of 70% for UTI [16].
Urine culture is indicated in complicated or recurrent UTI,
or if there are strong clinical signs of an infection but an-
tibiotics are not effective [17]. Urine samples collected af-
ter bladder catheterisation are considered pathological if
a single uropathogen species has ≥102cfu/ml; midstream
urine samples are considered to show relevant growth if
there are ≥105 cfu/ml.
Imaging: if there are ≥3 UTIs per year, cystoscopy is rec-
ommended to rule out intravesical pathology; if there are
≥2 pyelonephritis episodes per year, a kidney computed to-
mography (CT) scan (contrast CT) is recommended.
Treatment of acute urinary tract infections
Antibiotic-free approach
At least half of acute uncomplicated UTIs heal sponta-
neously, although symptoms persist longer than when
treated with antibiotics [18]. Requests by the patient for a
speedy relief of symptoms are common. In this new treat-
ment guideline, a delay in antibiotic administration for 48
hours is recommended for uncomplicated UTIs and pa-
tients under 65 years of age. Pain relief should primarily
be by the use of antibiotic-free treatments, such as non-
steroidal anti-inflammatory drugs (NSAIDs) with a phy-
totherapeutic agent or D-mannose [2, 5, 8]. Uva-ursi ex-
tract has been advocated as a phytotherapeutic agent for
the relief of symptoms of acute cystitis, although a recent
randomised placebo-controlled trial did not show a re-
duction in antibiotic use [19]. Ibuprofen 3 × 400 mg vs
ciprofloxacin 2 × 250 mg for 3 days had an equally good
effect on UTI symptoms after 4 days without any signifi-
cant difference in the rates of recurrence [20]. Both med-
ications are contraindicated in pregnancy.
However, two recent studies challenge the efficacy and
safety of NSAIDS. A study from Switzerland reported
inferiority of diclofenac to norfloxacin by day 4 and a
higher risk of pyelonephritis, even though it reduced an-
tibiotic use in women with an uncomplicated lower UTI
[21]. Another recent study from Scandinavia reported that
in patients with uncomplicated UTI, ibuprofen 600 mg
three times daily was inferior to pivmecillinam, which
is not available in Switzerland. All cases of secondary
pyelonephritis occurred in the ibuprofen group [22]. Com-
pared with fosfomycin, initial treatment with ibuprofen
substantially reduced antibiotic use in women aged 18−65
with mild to moderate symptoms of UTI, but was less ef-
fective for symptom relief, and there were more cases of
pyelonephritis [23]. Therefore, close clinical observation
or follow-up for potential signs of pyelonephritis are indi-
cated if lower UTIs are treated with NSAIDs. In addition,
the NSAID treatment regimen should be discussed with
women who want to avoid antibiotics or who are open to a
delayed prescription.
An antibiotic prescription could be given to specific pa-
tients, such as those who plan to travel. Physicians should
enquire about allergies.
Table 2: Categories of UTI.
Uncomplicated UTI Complicated UTI Asymptomatic bacteriuria
Patients Women without anatomical or functional
abnormalities of the genitourinary tract
Pregnancy, risk factors such as poorly controlled di-
abetes mellitus, hospital-acquired infections, kidney
disease, previous kidney transplant, urolithiasis,
anatomical, functional abnormality (genital pro-
lapse), immunosuppressants, indwelling catheter,
postoperative (predisposing factors)
Any person, pregnant or non-pregnant
Clinical signs UTI (dysuria, pollakiuria, suprapubic
pain), pyelonephritis (as UTI with addition
of flank or groin pain, fever)
Recurrent UTI with risk factors (see above), previ-
ously treated with NSAIDs and/or antibiotics,
pyelonephritis.
No clinical signs
Diagnostics Not required for first episode of UTI;
Recommended for pyelonephritis and re-
currence: urine analysis, culture
Suspected pyelonephritis: ultrasound
Urine analysis, urine culture
Suspected pyelonephritis: kidney ultrasound,
postvoid residual urine, in pregnancy also measure
cervical length
Fever >38.3°C and hospitalised patients: blood cul-
tures (2×)
Not required except before urological interven-
tions with risk or probability of vesical mucosa le-
sions/damage
Microbiology E. coli (>80%) (also ESBL), Proteus
mirabilis, Klebsiella spp, Staphylococcus
saprophyticus, Enterococcus faecalis
E. coli (also ESBL), Enterococcus faecalis, Enter-
obacterales, Pseudomonas aeruginosa
Any kind of bacteria in an amount of ≥105 bacte-
ria per ml
ESBL = extended spectrum beta-lactamase; NSAID = nonsteroidal anti-inflammatory drug
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Antibiotic therapy in uncomplicated and complicated
UTIs
If symptoms persist after 48 hours, starting an antibiotic is
indicated. Also, ascending pain indicates a possible upper
urinary infection and calls for the direct administration of
antibiotics. Antibiotics may also be promptly prescribed to
persons over 65 years of age, because this group of patients
is more susceptible to urosepsis or UTI-associated comor-
bidities. As revealed by a national Danish study, the imple-
mentation of the new antibiotics guideline with avoidance
of or delayed antibiotic administration led to an increase in
pyelonephritis and urosepsis in UTI patients over 65 years
of age [24].
Uncomplicated UTIs can be treated empirically. In urgent
cases with clear symptoms, pharmacists (in Switzerland)
are allowed to provide medication, including antibiotics
from the specialty list.
The therapy options for simple UTIs and pyelonephritis are
summarised in table 3 and for complicated UTIs in table
4 [25], taking into account antibiotic resistance in Switzer-
land (www.anresis.ch). The Swiss Centre for Antibiotic
Resistance provides resistance data obtained by passive
surveillance, which overestimates the true resistance rate.
The actual resistance patterns of uropathogens in primary
care in Switzerland (2019) are reported by Plate et al.
[26]. In this study, E. coli showed low resistance rates to
the recommended first-line antibiotics. Further, resistance
to trimethoprim/sulphamethoxazole was significantly low-
er than reported by ANRESIS, making trimethoprim/sul-
famethoxazole a suitable and cheap alternative for the em-
pirical treatment.
The quinolone resistance rates of E.coli have increased
from 1% to 21% in the past 10 years, and its resistance
against third and fourth generation cephalosporins has in-
creased from 1% to 9%. The resistance rates of E. coli to
fosfomycin and nitrofurantoin remain very low. Therefore,
consistent with the guidelines of the Infectious Disease So-
ciety of America and the European Society for Microbi-
ology and Infectious Disease from 2011, fosfomycin and
nitrofurantoin, as well as cotrimoxazole, can still be rec-
ommended as a first choice therapy.
Table 3: Antibiotic therapy for uncomplicated UTIs and pyelonephritis in non-pregnant women.
Level of resistance in Switzer-
land for community-acquired
E. coli, www.anresis.ch
Dosage Duration of treat-
ment
Remarks
Uncomplicated UTIs, first choice
Nitrofurantoin 1.0% 2 × 100 mg/day 5 days Not effective for pyelonephritits, low tissue ab-
sorption
Minimal development of resistance, minimal
“collateral damage“
Severe side effects rare (pulmonary fibrosis,
liver insufficiency, neuropathy)
GFR ≥60ml/min
Fosfomycin 1.5% 1 × 3 g Single dose Not effective for pyelonephritits
Administered in the evening 2−3 hours before
or after meal
Mainly gastrointestinal side effects
Trimethoprim/
sulfamethoxazole
23.5% 2 × 800/160 mg/day 3−5 days Side effects: nausea, vomiting, diarrhoea, rare
rash (Stevens-Johnson syndrome), jaundice,
iatrogenic lupus, leuco- and thrombocytopenia
Lowers levels of oral contraceptives
Uncomplicated UTIs, second choice
Ciprofloxacin 19.0% 2 × 500 mg/day 3 days
Amoxicillin or
amoxicillin/clavulanic acid




23.5% 2 × 800/160 mg/day (7−)14 days
Ciprofloxacin 19.0% 2 × 500 mg/day 7 days Empirical use only if resistance rate in E. coli
<10%
Absorption reduced by milk products
Ceftriaxone
(third generation cephalosporin)
9.1% 2 g/day intravenously 7−14 days Hospitalisation or outpatient intravenous thera-
py
Table 4: Antibiotic therapy for complicated UTIs in non-pregnant women.









14.2% 2 × 1 g/day
or









23.5% 2 × 800/160 mg/day 3−5 days −
Fosfomycin
(third choice)
1.5% 1 × 3 g every 2−3 days 3 cycles −
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The guideline of the Swiss Society of Infectious Disease
dating from February 2020 classified fosfomycin as a sec-
ond choice drug owing to its lower efficacy compared with
nitrofurantoin shown in the study by Huttner et all [27].
The proportion of treatment failures is high and patients
should be informed. In a randomised clinical trial that in-
cluded 513 women with uncomplicated UTIs, clinical res-
olution at 28 days occurred in 70% of patients treated for 5
days with nitrofurantoin vs 58% of patients who received a
single dose of fosfomycin. This is a statistically significant
difference; however, nitrofurantoin was given at a dose of
100 mg three times daily, which is not the recommended
dosage in Switzerland (100 mg twice daily) [27]. Never-
theless, fosfomycin 3 g, as a single dose, is a convenient,
well tolerated and efficient therapy; considering the resis-
tance rate, it is better than trimethoprim/sulfamethoxazole.
In clinical practice it is still, in our opinion, a valuable first-
choice option. Lopes-Montesinos and Horcajada [28] re-
viewed the use of oral and intravenous fosfomycin to treat
complicated UTIs. Because some bacteria are multidrug-
resistant, they evaluated fosfomycin as an antibiotic with
enormous potential; randomised studies are under way.
Doesschate et al. [29] conducted a double-blind placebo-
controlled randomised non-inferiority trial (FORECAST)
comparing fosfomycin with ciprofloxacin in complicated
UTIs. They demonstrated non-inferiority of oral fosfomyin
3 g every 24 hours compared with oral ciprofloxacin 500
mg every 12 hours for 10 days, both given after at least
48 hours of intravenous treatment. When complicated UTI
was treated with multiple-dose fosfomycin, clinical resolu-
tion occurred in two of three treatment episodes [30].
A study of the treatment of ASB showed that patients
who were not treated had less recurrence than patients
treated with antibiotics, and that the resistance rate of the
E.coli was lower. In contrast to previous opinions, asymp-
tomatic diabetic patients should not be treated [31]. In cas-
es of acute pyelonephritis, antibiotic therapy for 7 days
has proven to be as effective as the 14 days of therapy
used previously [32] (LoE Ib). Complicated UTIs should
be treated with a 7- to 10-day antibiotic regimen.
Alternative approaches to conventional treat-
ment
As a result of increasing levels of antibiotic resistance,
especially to trimethoprim/sulfamethoxazole and
quinolones, and increasing awareness of the detrimental
effects of antibiotics on the microbiome, antibiotic-free
therapies are becoming increasingly important. Alternative
options should be recommended to all patients with recur-
rent infections.
The following recommendations reduce the frequency of
recurrence:
– Adequate fluid intake (additional 1.5 to 2 litres/day),
check that urine is clear and postcoital micturition with-
in an hour. The latter recommendation has not been test-
ed in studies, but there is empirical evidence supporting
it [33] (LoE IV).
– Avoid contraceptive spermicides (LoE III).
– Correct anal hygiene, cleaning from front to back (LoE
III).
– No intravaginal rinses or disinfectants (LoE III).
– Avoid getting cold and cold drinks (LoE IIb).
The following medications or solutions reduce the frequen-
cy of recurrence and can be recommended during the acute
phase of a UTI, but not during pregnancy:
– D-mannose for prophylaxis; D-mannose binds to bacte-
rial pili and thereby reduces the adherence of E. coli to
the urothelium. A study of women with recurrent UTIs
compared the effect of prescribing D-mannose, nitrofu-
rantoin or a placebo over a 6-month period. This
showed that D-mannose (2 g/day) and nitrofurantoin
(50 mg/day) were equally effective, but the former had
significantly fewer side effects [34] (LoE Ib).
– Topical oestrogen reduces UTIs in postmenopausal
women [35]. A randomised study of 93 postmenopausal
women with recurrent UTIs comparing the use of in-
travaginal oestrogen (0.5 mg for the first 2 weeks, then
twice weekly) over 8 months with the use of a placebo,
showed a significant reduction in UTI frequency: 0.5
versus 5.9 episodes per patient per year [36] (LoE Ib).
A study also showed beneficial effects of localised oe-
strogen in premenopausal women using combined con-
traception [37] (LoE III). Localised oestrogen should
not be the first-choice recommendation for patients
with oestrogen-dependent gynaecological carcinomas,
but in cases where alternative therapies have not been
effective, there is clinical evidence and safety data sup-
porting low doses of oestriol (50 µg/g) [38].
– Cranberry capsules (or juice) contain proanthocyani-
dine, which inhibits the adherence of the fimbriae of
E.coli to the urothelium. The studies are inconsistent
and there is no clear evidence to support its use in UTIs
[39] (LoE III). Overall, the clinical use of cranberries
remains questionable, because there is a lack of high
quality evidence.
– OM-89 (Uro-Vaxom®), a lyophilised extract of 18 dif-
ferent uropathogenic strains of E.coli, reduces the fre-
quency of UTIs by 40−50% (LoE IIa).
– Intravesical use of hyaluronic acid and chondroitin sul-
phate builds up the glycosaminoglycan layer of the
bladder and can be used as prophylactic treatment for
recurrent UTIs [40] (LoE Ia). Some health insurance
providers do not cover this treatment, whereas others
do; this situation is currently being discussed with the
health insurance companies.
– Acidification of urine with methenamine salts occurs
through the production of formaldehyde, which is bac-
teriostatic. There is evidence that this is carcinogenic in
long term animal testing (LoE IIa). A Cochrane analy-
sis showed beneficial results of acidification of urine in
patients without urinary tract abnormalities or catheters,
but not in patients with structural abnormalities [41].
Methenamine can be considered as a short-term therapy
(LoE Ia).
– Utipro®plus: xyloglucan and gelatine build a biofilm re-
ducing bacterial adherence in intestine with associated
changes in the intestinal microbiome; propolis and hi-
biscus lead to the acidification of urine. A randomised
study where two Utipro®plus capsules/day were added
to ciprofloxacin, followed by one capsule/day for 15
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days showed a significant reduction (−19.4%) in the
frequency of recurrence of UTI compared with placebo
[42] (LoE IIb).
– Angocin®: active ingredients are mustard oils (isothio-
cyanates) from nasturtium and horseradish root. An-
gocin® showed good efficacy when used for recurrent
UTIs [43] (LoE Ib).
– Uva-ursi extract has been advocated for relief of symp-
toms of acute cystitis although a recent randomised
placebo-controlled trial did not show a reduction in an-
tibiotic use [19].
– Vaccination with extraintestinal E. coli (ExPEC4V)
[44]. This vaccine is in phase Ib of clinical testing. It
was well tolerated and no side effects were seen (LoE
experim.).
– Probiotics and lactobacillus drinks are not recommend-
ed as UTI prophylaxis, probably because no optimal
formulations have been identified yet. New data show
beneficial outcomes from Lactobacillus crispatus ap-
plied as an intravaginal ovule, and also for or L. rham-
nosus GR-1 and L. reuteri RC-14, which are being in-
vestigated further (LoE IIa).
– Vitamin C cannot be recommended for reducing UTIs,
because the results of two studies are contradictory. At
best, its only use might be as an acidifying additive
(LoE III).
– Stool transplants and changes to the urinary microbio-
me are currently under investigation (LoE experim.)
Pregnancy
In principle, there is an increased risk of pyelonephritis
and complications of pregnancy with both symptomatic
UTIs and ASB. Pregnant women with ASB are at a 20-
to 30-fold greater risk of developing pyelonephritis and
possible subsequent complications such as urosepsis, pre-
mature birth and SGA (small for gestational age) children
[45]. These older and methodologically questionable stud-
ies were the background reasoning behind the recommen-
dation for systematic screening for ASB in pregnant
women, including antibiotic therapy in cases with positive
cultures. Although a new randomised controlled study
showed that untreated ASB in pregnant women of a non-
risk group (see details below) increases the risk of devel-
oping pyelonephritis, there was no increased risk of pre-
mature birth or other neonatal or maternal complications.
These new data have been taken into consideration in a
new meta-analysis and other national guidelines. The ben-
efit of systematically screening all pregnant women for
ASB is currently not proven, but bacterial screening fol-
lowing vaginal smears in the first trimester continues to
be recommended [46, 47] (LoE 1a). Systematic screening
of all pregnant women for ASB can no longer be recom-
mended, with the exception of pregnant women at risk ow-
ing to factors such as diabetes mellitus, immunosuppres-
sion, functional or structural abnormalities of the urinary
tract, previous episodes of pyelonephritis, previous prema-
ture births or late pregnancy loss.
Current data show that a single dose of antibiotic, 3 g fos-
fomycin, is sufficient in pregnancy [31, 48], but is not rec-
ommended in cases with an increased risk of premature
birth, when more prolonged therapy should be given.
Ibuprufen and chinolones like ciprofloxacin are both con-
traindicated in pregnancy.
Antibiotic therapy for uncomplicated UTI and
pyelonephritis during pregnancy and breastfeeding is sum-
marised in table 5.
Asymptomatic bacteriuria
It is not necessary to routinely screen non-pregnant women
for asymptomatic bacteriuria, nor to treat it if incidentally
discovered [49]. A study of the treatment of ASB showed
that patients who were not treated had fewer recurrences
than patients treated with antibiotics and that the resistance
rate of E.coli was lower. In contrast to previous opinions, it
is now recommended that asymptomatic diabetic patients
should not be treated [31]. The study by Kazemier inves-
tigated the maternal and neonatal consequences of treated
and untreated ASB in pregnancy [50]. The conclusion of
the study was that the non-treatment of ASB in pregnant
women is an option. As mentioned above, systematic
screening for asymptomatic bacteriuria in pregnant women
is no longer recommended, with the exception of pregnant
women at risk owing to factors such as diabetes mellitus,
immunosuppression, functional or structural abnormalities
of the urinary tract, previous episodes of pyelonephritis,
previous premature births or late pregnancy loss [51].
Testing for and treating of ASB is not recommended ex-
cept for selected indications (see section below “Antibiotic
prophylaxis before a urological procedure”).
Prophylaxis
Antibiotic prophylaxis is no longer indicated before surgi-
cal interventions such as hip or knee prosthesis or gynae-
cological operations such as hysterectomies [46]. Kidney
transplant recipients are a special case [52]. More recent
Table 5: Antibiotic therapy for uncomplicated UTI and pyelonephritis during pregnancy and breastfeeding.
Level of Resistance in
Switzerland
for community- acquired E.
coli,
www.anresis.ch





14.2% 2 − 1 g/day
or
3 − 625 mg/day










23.5% 2 − 800/160 mg/day 3−5 days Contraindicated in first and third trimester;
suitable during breastfeeding
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data show that UTIs could significantly impact on graft
function and long-term outcomes, and that the prevention
and early treatment of UTI is of importance, especially in
the first 6 months after transplantation. For information on
the dosage for see reference [52].
Pregnancy is another situation where the significance of a
prophylactic treatment of ASB is possibly of value. Stud-
ies that have a different outcome are discussed above in the
sections on “Pregnancy” and “Asymptomatic bacteriuria”.
Antibiotic prophylaxis before a urological procedure
Cystoscopy and urodynamic studies
Prophylactic antibiotics are not indicated before cys-
toscopy or urodynamic assessment unless the physician re-
sponsible makes another decision based on experience and
on the individual case. Eradication of ASB is not necessary
[53] (LoE IV) except when it comes to mucosal lesions/
damage as in, for example, bladder biopsies, for which
prophylaxis is indicated. Routine antibiotic prophylaxis
should be avoided in urodynamic assessment to investigate
urinary stress incontinence in cases of genital prolapse,
provided that there is no significant postvoid residual urine
(<100 ml). Patients with a cystocele are more likely to have
microhaematuria than those without a cystocele, but this is
not associated with infection. Important: UTIs must be ex-
cluded before any urogynaecology intervention, or treated
as necessary (LoE Ib).
Antibiotic prophylaxis before or directly after urodynamic
assessment or cystoscopy can be considered in cases where
patients have recurrent UTIs, postvoid residual urine >100
ml, neurological bladder dysfunction, age ≥ 70 years, pres-
ence of indwelling catheter or immunocompromise. Rec-
ommended antibiotics include trimethoprim/sulfamethoxa-
zole 800/160mg or fosfomycin 3 g sachet single dose [54]
(LoE IIa).
Incontinence and prolapse operations
Single-dose antibiotic prophylaxis with a first generation
cephalosporin (cefazolin, 30 minutes before skin incision)
is recommended, although according to the latest review
from the US Centers for Disease Control and Prevention,
there is only moderate evidence supporting this [55] (LoE
IIb). Extended antibiotic therapy should not be given if the
postoperative recovery is without complications, and al-
so should not be given following mesh operations (sacro-
colpopexy, incontinence slings and vaginal meshes) [56].
A published decision analysis model suggests that antibi-
otic prophylaxis is probably not required before the inser-
tion of mid-urethral slings [57]. Postoperative antibiotic
prophylaxis after urogynaecological procedures requiring
intermittent self-catheterisation is not indicated [58] (LoE
IV).
Postoperative bladder atony, increased postvoid residual
urine
Postoperative postvoid residual urine, catheterisation for
>24 hours or repeated catheterisation, are risk factors for
urinary tract infections. Nevertheless, prolonged postop-
erative prophylactic antibiotic therapy in these situations
remains controversial and, based on current evidence, is
not recommended [59]. Measuring postvoid residual urine
postoperatively using ultrasound is preferable to measur-
ing repeatedly with single-use catheters. If recurrent UTIs
occur beyond the immediate postoperative period, it is nec-
essary to establish the cause (fistula, mesh erosion) (LoE
Ia).
If it is necessary to drain the bladder long-term postopera-
tively because of increased postvoid residual urine, supra-
pubic drainage is preferable to transurethral. No difference
is seen in the occurrence of bacteriuria or UTIs with in-
termittent self-catheterisation using hydrophilic coated sin-
gle-use catheters or suprapubic catheterisation [60].
Treatment and prophylaxis of recurrent UTIs
For recurrent UTIs there is a distinction between a relapse
(UTI due to the same pathogen within two weeks of ending
therapy) and a reinfection (new UTI more than 2 weeks
after ending therapy, usually due to a different pathogen).
Reinfections are twice as frequent and should be treated
with the same medication for the same duration as the first
infection (LoE Ia). If there are no predisposing factors, it
is also possible to treat following a self-diagnosis, which is
appreciated by many women. Easy to handle infection-spe-
cific Combur®-Strip tests with three fields are available.
In the case of frequent recurrence, antibiotic prophylaxis
over a period of 6 months can be considered as a last resort
(table 6), either to be taken continuously or only postcoital-
ly if sexual intercourse is the cause. Continuous and post-
coital low-dose antibiotic prophylaxis are equally effective
in reducing recurrent UTIs.
Discussion and areas of future research
Uncomplicated UTIs are ideally treated with antibiotic
treatment delayed by 48 hours if symptoms persist. This
recommendation is in accordance with recent recommen-
dations of other societies that were published as a reaction
to the rise of antibiotic resistance [2, 5, 8].
Our expert opinion emphasises that primarily analgesics
such ibuprofen, immunomodulations/vaccines and phy-
totherapeutics should be used in the treatment of uncom-
plicated and recurrent UTIs in order to halt antibiotic re-
sistance. The global rise in antibiotic resistance has caused
the number of national and international guidelines ad-
dressing UTIs to increase in the last 2 years: from 2011
to 2017 no UTI guidelines were published or amended,
since 2018 six guidelines have been released, including our




6 months, then stop
Postcoital: within 30 minutes following sexual intercourse
Trimethoprim/
sulfamethoxazole
40/200 mg 1 ×/day or
40/2000 mg 3 ×/week
6 months, then stop
Postcoital: within 30 minutes following sexual intercourse
Fosfomycin 3 g every 7−10 days 6 months, then stop
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gender-specific guideline. The recommendations given in
these national and international publications with respect
to antibiotic-free therapies should help to contain antibiot-
ic resistance.
Another advantage of the antibiotic-free approach is that it
reduces the recurrence rate of UTIs [49]. Similarly, treat-
ment of ASB is obsolete. This also increasingly applies to
ASB in pregnancy, although the evidence with respect to
this issue is still somewhat weak.
Quinolones should be avoided in uncomplicated UTIs, be-
cause they can lead to potentially permanent side effects
affecting tendons, muscles, joints, nerves, blood vessels
and the central nervous system [62].
Gender-adapted and differentiated UTI treatment algo-
rithms for men and women and pregnant women are re-
quired, and will become important in the future.
Recent basic research uses polymerase chain reaction
(PCR) in urine cultures to investigate the effect of the blad-
der microbiome on urinary urge symptoms and UTIs [63,
64]. The bladder microbiome seems to be more complex
than previously thought and this begs a reappraisal of our
current testing in recurrent UTI. Future research will point
out the role of bacterial survival after treatment as well as
defects in urothelial barrier function that might contribute
to the failure to eradicate UTI.
On a clinical level, large randomised, double-blind studies
of alternative approaches to conventional treatment with
long follow-up are required.
Summary
– Routine screening for ASB should not be carried out,
and no treatment should be given if ASB is discovered
by chance, with the exception of patients prior to urog-
ynaecological surgery.
– Systematic screening of asymptomatic bacteriuria in
pregnant women is not recommended anymore. How-
ever, ASB in risk-groups or acute UTI should be treated
accordingly (table 2). Bacterial screening following
vaginal smears is still recommended for all pregnant
women.
– Acute UTIs should be treated as briefly as possible with
UTI-specific antibiotics (table 2).
– Patients should be informed that most UTIs are self-
limiting, that the symptoms can be relieved with non-
steroidal anti-inflammatory drugs and that the same
time is required to eradicate the bacteria using antibi-
otics or NSAIDs. This does not apply in pregnancy. At
the moment this issue is controversial.
– If no relief of symptoms is seen in a suspected recurrent
UTI, and if no leucocytes or bacteria are present in
catheter urine, a hyperactive bladder or bladder pain
syndrome should be considered. Repeat antibiotic treat-
ment is not recommended in this situation, and it is rec-
ommended to refer the patient to a centre with exper-
tise.
– Antibiotic therapy prior to or following urodynamic
testing or cystoscopy is only indicated in specific cases,
as discussed in this text. No endocarditis prophylaxis is
necessary prior to urodynamic testing.
– Incontinence or prolapse surgery with or without mesh:
moderate evidence for antibiotic prophylaxis prior to
surgery using first generation cephalosporins.
– There are various conservative options to prevent UTIs:
behavioural measures and antibiotic-free options should
be given priority given the increasing antibiotic resis-
tance.
– In cases with significant postvoid residual urine, the
cause should be identified. If this is not possible, inter-
mittent single-use or suprapubic drainage should be
used rather than transurethral drainage, without using
short or long-term antibiotic prophylaxis.
– There is no evidence that preoperatively recurring UTIs
can be reduced by prolapse surgery.
– New research approaches include adaptation of the uri-
nary microbiomes and vaccination against
uropathogens.
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